323 related articles for article (PubMed ID: 17916461)
1. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
Matharoo-Ball B; Ball G; Rees R
Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
[TBL] [Abstract][Full Text] [Related]
2. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
3. Proteomics in prostate cancer biomarker discovery.
Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
[TBL] [Abstract][Full Text] [Related]
4. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
Calvo KR; Liotta LA; Petricoin EF
Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
[TBL] [Abstract][Full Text] [Related]
5. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
Bharti A; Ma PC; Salgia R
Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
[TBL] [Abstract][Full Text] [Related]
6. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
Fredolini C; Liotta LA; Petricoin EF
Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
[TBL] [Abstract][Full Text] [Related]
7. Proteomics for the identification of new prostate cancer biomarkers.
Ornstein DK; Tyson DR
Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
[TBL] [Abstract][Full Text] [Related]
8. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
Armstrong AJ; Febbo PG
Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry: uncovering the cancer proteome for diagnostics.
van der Merwe DE; Oikonomopoulou K; Marshall J; Diamandis EP
Adv Cancer Res; 2007; 96():23-50. PubMed ID: 17161675
[TBL] [Abstract][Full Text] [Related]
10. Proteome informatics for cancer research: from molecules to clinic.
Brusic V; Marina O; Wu CJ; Reinherz EL
Proteomics; 2007 Mar; 7(6):976-91. PubMed ID: 17370257
[TBL] [Abstract][Full Text] [Related]
11. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
12. Cancer biomarkers: knowing the present and predicting the future.
Chatterjee SK; Zetter BR
Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
15. The role of proteomics in prostate cancer research: biomarker discovery and validation.
Pin E; Fredolini C; Petricoin EF
Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
[TBL] [Abstract][Full Text] [Related]
16. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
Christensen E; Evans KR; Ménard C; Pintilie M; Bristow RG
Cancer Metastasis Rev; 2008 Sep; 27(3):375-85. PubMed ID: 18427732
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for the development of cancer vaccines: current status.
Copier J; Whelan M; Dalgleish A
Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650
[TBL] [Abstract][Full Text] [Related]
18. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
Flaig TW; Nordeen SK; Lucia MS; Harrison GS; Glodé LM
J Urol; 2007 Apr; 177(4):1229-37. PubMed ID: 17382696
[TBL] [Abstract][Full Text] [Related]
19. Oral cancer proteomics.
Hu S; Wong DT
Curr Opin Mol Ther; 2007 Oct; 9(5):467-76. PubMed ID: 17932810
[TBL] [Abstract][Full Text] [Related]
20. Proteomics: new technologies and clinical applications.
Latterich M; Abramovitz M; Leyland-Jones B
Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
